Baidu
map

Diabetes:阿司匹林导致II型糖尿病病人过量表达异前列腺素

2012-03-31 towersimper 生物谷

II型糖尿病(type 2 diabetes mellitus, T2DM)患者用阿司匹林治疗后,过量表达异前列腺素(isoprostane),而这又会增强招募血小板的能力。相关研究结果于2012年3月16日在线发表在Diabetes期刊上。 因为注意到阿司匹林对II型糖尿病患者的心血管事件有着适度的影响,来自意大利罗马智慧大学(Sapienza University of Rome)的Robe

II型糖尿病(type 2 diabetes mellitus, T2DM)患者用阿司匹林治疗后,过量表达异前列腺素(isoprostane),而这又会增强招募血小板的能力。相关研究结果于2012年3月16日在线发表在Diabetes期刊上。

因为注意到阿司匹林对II型糖尿病患者的心血管事件有着适度的影响,来自意大利罗马智慧大学(Sapienza University of Rome)的Roberto Cangemi博士和同事们研究了阿司匹林对II型糖尿病患者产生血小板异前列腺素(isoprostane)的影响。他们对50名接受阿司匹林治疗的II型糖尿病患者和50名未接受相应治疗的II型糖尿病患者与100名未患糖尿病的病人在年龄、性别和动脉粥样硬化危险因素和阿司匹林治疗等方面进行比较。

研究人员在糖尿病病人而不是那些未患糖尿病的病人,接受阿司匹林治疗的糖尿病病人而不是未接受相应治疗的糖尿病病人中,观察到更强的血小板招募能力,更高的血小板异前列腺素水平,以及还原型NAD磷酸氧化酶(NAD phosphate oxidase, NOX2)受到激活。在所有接受阿司匹林治疗的病人当中,血小板凝血烷A2(thromboxane A2, TxA2)受到抑制。在这项干预性研究中,研究人员发现在患有糖尿病和未患上糖尿病的那些病人当中,阿司匹林类似地抑制血小板TxA2。在患有糖尿病的病人当中,他们同步观察到血小板招募能力增强,异前列腺素水平增加,NOX2激活,然而在未患有糖尿病的病人当中,他们没有观察到这些变化。

“我们证实II型糖尿病患者服用的低剂量阿司匹林通过上调NOX2产生的活性氧来提高血小板异前列腺素水平”,论文作者们写道,“这种影响减轻阿司匹林产生的抗血小板作用,从而可能解释为什么相比于其他动脉粥样硬化疾病,阿司匹林对II型糖尿病的疗效更低。”

doi:10.2337/db11-1243
Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin

Roberto Cangemi, Pasquale Pignatelli, Roberto Carnevale, Carmen Nigro, Marco Proietti, Francesco Angelico, Davide Lauro, Stefania Basili and Francesco Violi

Aspirin modestly influences cardiovascular events in patients with type 2 diabetes mellitus (T2DM), but the reason is unclear. The aim of the study was to determine whether in T2DM patients aspirin enhances platelet isoprostanes, which are eicosanoids with proaggregating properties derived from arachidonic acid oxidation by platelet NOX2, the catalytic subunit of reduced NAD phosphate oxidase. A cross-sectional study was performed comparing T2DM patients, treated (n = 50) or not treated (n = 50) with 100 mg/day aspirin, with 100 nondiabetic patients, matched for age, sex, atherosclerosis risk factors, and aspirin treatment. A short-term (7 days) treatment with 100 mg/day aspirin also was performed in 36 aspirin-free diabetic and nondiabetic patients. Higher platelet recruitment, platelet isoprostane, and NOX2 activation was found in diabetic versus nondiabetic patients and in aspirin-treated diabetic patients versus nontreated patients (P < 0.001). Platelet thromboxane (Tx) A2 (P < 0.001) was inhibited in all aspirin-treated patients. In the interventional study, aspirin similarly inhibited platelet TxA2 in diabetic and nondiabetic patients (P < 0.001). Platelet recruitment, isoprostane levels, and NOX2 activation showed a parallel increase in diabetic patients (P < 0.001) and no changes in nondiabetic patients. These findings suggest that in aspirin-treated diabetic patients, oxidative stress–mediated platelet isoprostane overproduction is associated with enhanced platelet recruitment, an effect that mitigates aspirin-mediated TxA2 inhibition.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900935, encodeId=785319009356f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Jul 06 12:28:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813902, encodeId=541718139025b, content=<a href='/topic/show?id=dd5e94131d0' target=_blank style='color:#2F92EE;'>#过量表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94131, encryptionId=dd5e94131d0, topicName=过量表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Feb 25 15:28:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744850, encodeId=f9f81e448509a, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Fri Mar 01 07:28:00 CST 2013, time=2013-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759124, encodeId=eafc1e591244e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 02 18:28:00 CST 2012, time=2012-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636484, encodeId=5f33163648428, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 08:28:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429654, encodeId=2cd11429654ff, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Mon Apr 02 03:28:00 CST 2012, time=2012-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1900935, encodeId=785319009356f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Jul 06 12:28:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813902, encodeId=541718139025b, content=<a href='/topic/show?id=dd5e94131d0' target=_blank style='color:#2F92EE;'>#过量表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94131, encryptionId=dd5e94131d0, topicName=过量表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Feb 25 15:28:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744850, encodeId=f9f81e448509a, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Fri Mar 01 07:28:00 CST 2013, time=2013-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759124, encodeId=eafc1e591244e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 02 18:28:00 CST 2012, time=2012-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636484, encodeId=5f33163648428, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 08:28:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429654, encodeId=2cd11429654ff, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Mon Apr 02 03:28:00 CST 2012, time=2012-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1900935, encodeId=785319009356f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Jul 06 12:28:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813902, encodeId=541718139025b, content=<a href='/topic/show?id=dd5e94131d0' target=_blank style='color:#2F92EE;'>#过量表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94131, encryptionId=dd5e94131d0, topicName=过量表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Feb 25 15:28:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744850, encodeId=f9f81e448509a, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Fri Mar 01 07:28:00 CST 2013, time=2013-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759124, encodeId=eafc1e591244e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 02 18:28:00 CST 2012, time=2012-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636484, encodeId=5f33163648428, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 08:28:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429654, encodeId=2cd11429654ff, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Mon Apr 02 03:28:00 CST 2012, time=2012-04-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1900935, encodeId=785319009356f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Jul 06 12:28:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813902, encodeId=541718139025b, content=<a href='/topic/show?id=dd5e94131d0' target=_blank style='color:#2F92EE;'>#过量表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94131, encryptionId=dd5e94131d0, topicName=过量表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Feb 25 15:28:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744850, encodeId=f9f81e448509a, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Fri Mar 01 07:28:00 CST 2013, time=2013-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759124, encodeId=eafc1e591244e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 02 18:28:00 CST 2012, time=2012-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636484, encodeId=5f33163648428, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 08:28:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429654, encodeId=2cd11429654ff, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Mon Apr 02 03:28:00 CST 2012, time=2012-04-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1900935, encodeId=785319009356f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Jul 06 12:28:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813902, encodeId=541718139025b, content=<a href='/topic/show?id=dd5e94131d0' target=_blank style='color:#2F92EE;'>#过量表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94131, encryptionId=dd5e94131d0, topicName=过量表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Feb 25 15:28:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744850, encodeId=f9f81e448509a, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Fri Mar 01 07:28:00 CST 2013, time=2013-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759124, encodeId=eafc1e591244e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 02 18:28:00 CST 2012, time=2012-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636484, encodeId=5f33163648428, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 08:28:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429654, encodeId=2cd11429654ff, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Mon Apr 02 03:28:00 CST 2012, time=2012-04-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1900935, encodeId=785319009356f, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Jul 06 12:28:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813902, encodeId=541718139025b, content=<a href='/topic/show?id=dd5e94131d0' target=_blank style='color:#2F92EE;'>#过量表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94131, encryptionId=dd5e94131d0, topicName=过量表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Feb 25 15:28:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1744850, encodeId=f9f81e448509a, content=<a href='/topic/show?id=37c3325555a' target=_blank style='color:#2F92EE;'>#前列腺素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32555, encryptionId=37c3325555a, topicName=前列腺素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7035453721, createdName=makuansheng, createdTime=Fri Mar 01 07:28:00 CST 2013, time=2013-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759124, encodeId=eafc1e591244e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Jun 02 18:28:00 CST 2012, time=2012-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636484, encodeId=5f33163648428, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Feb 18 08:28:00 CST 2013, time=2013-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429654, encodeId=2cd11429654ff, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Mon Apr 02 03:28:00 CST 2012, time=2012-04-02, status=1, ipAttribution=)]

相关资讯

Ann Neurol:阿司匹林弱化反式脂肪的负面影响

  3月1日,在线发表于《神经病学年鉴》(Ann Neurol)的一项前瞻性队列研究发现,反式脂肪摄入量较高与新发缺血性卒中有关,这种相关性与重要的生活方式/饮食因素无关。阿司匹林可弱化反式脂肪摄入对缺血性卒中的潜在不良影响。   该研究旨在考查饮食脂肪摄入量和绝经后妇女缺血性卒中的相关性。研究共纳入87025名大体上健康的绝经后妇女(50— 79岁)。通过病人自已填写所吃食物频度的问卷调查表,

Thromb Haemost:阿司匹林不会增加颅出血复发风险

近日,国际医学期刋《血栓形成与止血》Thrombosis and Haemostasis上刊登了香港大学研究人员的一项研究发现,研究者发现颅内出血的康复者如其后因心血管问题而使用阿司匹林,并不会增加其颅内出血的复发风险。 据介绍,阿司匹林是一种非常普遍而重要的心血管病药物,可用作治疗冠心病、缺血性中风、周围血管疾病等。但由于阿司匹林会增加病人出血的风险,如颅内出血,因此通常被医生认为是“不安

阿司匹林预防癌症应有年龄限制

 在美国临床肿瘤学会(ASCO)主办的胃肠道肿瘤会议上,英国牛津大学胃肠肿瘤学教授Janusz A. Jankowski博士指出,阿司匹林在预防食管癌和其他癌症方面的安全性和有效性可能会限制其在极高危患者中的应用。 证据表明,阿司匹林可使癌症风险降低1/4,但该药需服用至少10年才能看到具有临床意义的获益(Lancet 2011;377:31-41),这意味着副作用必须很低才行。

Cancer Cell:阿司匹林或有助抗癌

2月14日,澳大利亚研究人员称,阿司匹林等非甾体抗炎症药物或许能够抑制癌细胞扩散,原因是它们有助于切断输送这类细胞的“高速公路”。 长期以来,研究人员推测,阿司匹林等非甾体抗炎药可帮助抑制恶性肿瘤扩散,却没有能在药理层面解释作用机理。 墨尔本彼得·麦卡勒姆癌症研究中心研究人员14日说,“阿司匹林这类药物的分子……能有效抑制淋巴管扩张,从而削弱肿瘤扩散至身体其他部位的能力”。 在由美国《癌细胞

一种有望抗多种癌症的阿司匹林杂合物(NOSH-aspirin)被研发

研究人员将两种阿司匹林衍生物结合在一起形成一种新的杂合物,在实验室测试中,它似乎比其中任何一种衍生物更加有效地控制几种类型癌症的生长。他们在ACS Medicinal Chemistry Letters期刊上报道了这种新的杂合物NOSH-阿司匹林(NOSH-aspirin),如此命名是因为它释放一氧化氮(NO)和硫化氢(H2S)。 研究人员Khosrow Kashfi、Ravinder Kode

Lancet:阿司匹林具有非凡抗癌效用

3月21日,据英国广播公司报道,发表在英国医学杂志《柳叶刀》Lancet上的三项最新研究结果为阿司匹林的抗癌效果提供了有力的证据。 研究结果显示,每天服用少量阿司匹林可以预防癌症,甚至可以治疗癌症。 此前已经有许多人每天服用阿司匹林,以此来预防心脏病和中风的发生。 但是专家警告说,目前仍然没有充足的证据令医生向人们提出为了预防癌症而服用阿司匹林的建议。专家同时警告说,阿司匹林存在危险的副作用

Baidu
map
Baidu
map
Baidu
map